Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 16Triple Negative Breast Neoplasms 13Colorectal Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 7Stomach Neoplasms 6Lymphoma 6Uterine Cervical Neoplasms 5Ovarian Neoplasms 5Lung Neoplasms 4Liver Neoplasms 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Advanced Solid Tumor 3Solid Tumors 2Solid Tumor, Adult 2Recurrence 2Rectal Neoplasms 2

Interventions

ruxolitinib 7givinostat hydrochloride 3givinostat 3anagrelide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2spartalizumab 1sonidegib 1sabatolimab 1navitoclax 1lestaurtinib 1imetelstat 1ON 01910 1NIS-793 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1INCB057643 1Fentanyl 1Diagnosis 1Decitabine 1Celecoxib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thrombocythemia, Essential × spartalizumab × Clear all
NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Novartis

Phase 1 Withdrawn
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡